Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma Clinical Trial
Official title:
A Multi-center, Open Label, Single Arm, Multiple Dose Study to Assess the Pharmacokinetics of RO5072759 in Chinese Patients With CD20+ Malignant Disease.
This multi-center, open-label, single-arm study will evaluate the pharmacokinetics and safety of RO5072759 (GA101) in patients with CD20+ malignant lymphoma. Patients will receive multiple doses of RO5072759 (GA101). The anticipated time on study treatment is 24 weeks.
n/a
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment